BC Week In Review | Jun 30, 2014
Company News

Senesco management update

Senesco Technologies Inc. (OTCQB:SNTI), Bridgewater, N.J.   Business: Cancer, Autoimmune, Agbio/Environmental   Hired: Ronald Martell as CEO, formerly president and CEO of NeurogesX Inc. ; he succeeds Vaughn Smider, who remains CSO and a director...
BC Innovations | Oct 31, 2013
Targets & Mechanisms

KCC2 escape from neuropathic pain

A Canadian team has published preclinical proof of concept that activating a transporter called KCC2 represents a new mechanism for treating neuropathic pain. 1 The group expects that compounds against the ion transporter will be...
BC Week In Review | Jul 15, 2013
Company News

Acorda, NeurogesX deal

Acorda acquired development and commercialization rights in territories that Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) does not hold rights, including the U.S., Canada and Latin America, to two neuropathic pain management products - Qutenza capsaicin and...
BC Week In Review | Mar 18, 2013
Clinical News

Qutenza capsaicin regulatory update

Marketing partner Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) said the European Commission approved an expanded label for Qutenza 8% capsaicin patch to include use with pretreatment options, including oral analgesics or topical anesthetics. The dermal...
BC Week In Review | Mar 18, 2013
Company News

NovaBay management update

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) Emeryville, Calif.   Business: Infectious   Hired: Keith Bley as SVP of product development, formerly SVP of nonclinical R&D at NeurogesX Inc. ; he replaces Behzad Khosrovi, who is retiring  ...
BC Innovations | Jan 10, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular atrophy Transient receptor potential vanilloid 1 (TRPV1; VR1) In vitro and mouse studies suggest activating TRPV1 in skeletal muscle...
BC Week In Review | Aug 13, 2012
Clinical News

Qutenza capsaicin update

NeurogesX said marketing partner Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) began the open-label, European ELEVATE trial to compare a single application of up to 4 Qutenza patches vs. oral pregabalin in about 526 patients with...
BC Week In Review | Jul 9, 2012
Financial News

NeurogesX financial update

NeurogesX was delisted from NASDAQ for failure to comply with the exchange's listing requirements. The company is now listed on the OTC Bulletin Board under "NGSX." NeurogesX Inc. (OTCBB: NGSX), San Mateo, Calif.   Business:...
BioCentury | May 7, 2012
Strategy

Jazz's big band sound

A 2008 decision to concentrate on its commercial business has paid off for Jazz Pharmaceuticals Inc. The company has quadrupled its revenues, reduced its debt and increased its number of marketed drugs tenfold with two...
BC Week In Review | Apr 30, 2012
Financial News

NeurogesX financial update

NeurogesX received a letter from NASDAQ indicating that the company has not regained compliance with the minimum $50 million market value requirement for continued listing. The company intends to request a hearing. NeurogesX Inc. (NASDAQ:NGSX),...
Items per page:
1 - 10 of 177
BC Week In Review | Jun 30, 2014
Company News

Senesco management update

Senesco Technologies Inc. (OTCQB:SNTI), Bridgewater, N.J.   Business: Cancer, Autoimmune, Agbio/Environmental   Hired: Ronald Martell as CEO, formerly president and CEO of NeurogesX Inc. ; he succeeds Vaughn Smider, who remains CSO and a director...
BC Innovations | Oct 31, 2013
Targets & Mechanisms

KCC2 escape from neuropathic pain

A Canadian team has published preclinical proof of concept that activating a transporter called KCC2 represents a new mechanism for treating neuropathic pain. 1 The group expects that compounds against the ion transporter will be...
BC Week In Review | Jul 15, 2013
Company News

Acorda, NeurogesX deal

Acorda acquired development and commercialization rights in territories that Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) does not hold rights, including the U.S., Canada and Latin America, to two neuropathic pain management products - Qutenza capsaicin and...
BC Week In Review | Mar 18, 2013
Clinical News

Qutenza capsaicin regulatory update

Marketing partner Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) said the European Commission approved an expanded label for Qutenza 8% capsaicin patch to include use with pretreatment options, including oral analgesics or topical anesthetics. The dermal...
BC Week In Review | Mar 18, 2013
Company News

NovaBay management update

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) Emeryville, Calif.   Business: Infectious   Hired: Keith Bley as SVP of product development, formerly SVP of nonclinical R&D at NeurogesX Inc. ; he replaces Behzad Khosrovi, who is retiring  ...
BC Innovations | Jan 10, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular atrophy Transient receptor potential vanilloid 1 (TRPV1; VR1) In vitro and mouse studies suggest activating TRPV1 in skeletal muscle...
BC Week In Review | Aug 13, 2012
Clinical News

Qutenza capsaicin update

NeurogesX said marketing partner Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) began the open-label, European ELEVATE trial to compare a single application of up to 4 Qutenza patches vs. oral pregabalin in about 526 patients with...
BC Week In Review | Jul 9, 2012
Financial News

NeurogesX financial update

NeurogesX was delisted from NASDAQ for failure to comply with the exchange's listing requirements. The company is now listed on the OTC Bulletin Board under "NGSX." NeurogesX Inc. (OTCBB: NGSX), San Mateo, Calif.   Business:...
BioCentury | May 7, 2012
Strategy

Jazz's big band sound

A 2008 decision to concentrate on its commercial business has paid off for Jazz Pharmaceuticals Inc. The company has quadrupled its revenues, reduced its debt and increased its number of marketed drugs tenfold with two...
BC Week In Review | Apr 30, 2012
Financial News

NeurogesX financial update

NeurogesX received a letter from NASDAQ indicating that the company has not regained compliance with the minimum $50 million market value requirement for continued listing. The company intends to request a hearing. NeurogesX Inc. (NASDAQ:NGSX),...
Items per page:
1 - 10 of 177